BCL2L11 and gastrointestinal stromal tumor: In contrast, GIST-T1 cells treated with imatinib required less BIM peptide for MOMP and TMRE staining loss (Supplementary Fig. 1, greyscales in Supplementary Figs. 2 and 3).